期刊文献+
共找到5,765篇文章
< 1 2 250 >
每页显示 20 50 100
皮下免疫与舌下免疫治疗变应性鼻炎的临床疗效分析 认领
1
作者 孙楚东 郝钧 +1 位作者 罗丽华 肖蒙 《标记免疫分析与临床》 CAS 2020年第6期957-961,共5页
目的探讨皮下免疫(SCIT)与舌下免疫(SLIT)治疗变应性鼻炎的临床疗效及安全性。方法2012年3月至2016年3月期间,在我科门诊行变应性鼻炎免疫治疗患者92例,随机分为两组:SCIT组46例,SLIT组46例。两组治疗疗程为2年,均分剂量累加阶段和剂量... 目的探讨皮下免疫(SCIT)与舌下免疫(SLIT)治疗变应性鼻炎的临床疗效及安全性。方法2012年3月至2016年3月期间,在我科门诊行变应性鼻炎免疫治疗患者92例,随机分为两组:SCIT组46例,SLIT组46例。两组治疗疗程为2年,均分剂量累加阶段和剂量维持阶段。分别观察两组患者1年后,2年后的治疗疗效、症状改善情况、不良反应情况。结果治疗1年后:SCIT组有效率60.86%,鼻部症状评分(四种症状评分之和平均分值,以下同)为:4.68±0.89,不良反应发生率21.74%;SLIT组有效率56.21%,鼻部症状评分为:4.36±0.66,不良反应发生率8.69%。两组患者治疗的有效率及鼻部症状评分比较,差异无统计学意义(P>0.05);不良反应发生率SLIT组明显较低,差异有统计学意义(P<0.05)。治疗2年后:SCIT组有效率76.08%,鼻部症状评分为:2.99±0.86,不良反应发生率为28.26%。SLIT组有效率71.74%,鼻部症状评分为:2.76±0.65,不良反应发生率为:13.04%。两组患者的有效率及鼻部症状评分比较,差异无统计学意义(P>0.05);不良反应发生率SLIT组明显较低,差异有统计学意义(P<0.05)。两组患者治疗1年后及2年后的有效率及鼻部各种症状评分比较,差异有统计学意义(P<0.05)。结论皮下免疫与舌下免疫治疗变应性鼻炎的疗效相当;两组免疫治疗的时间周期越长,疗效越好;SLIT治疗变应性鼻炎安全性更好,值得推广。 展开更多
关键词 变应性鼻炎 免疫疗法 舌下免疫治疗 皮下免疫治疗
在线阅读 下载PDF
Research progress of triple-negative breast cancer immunotherapy 认领
2
作者 Jin-Feng Liu 《肿瘤微环境研究》 2020年第2期60-65,共6页
Breast cancer is the most common type of female malignancy in the world.Triple-negative breast cancer refers to breast cancer in which the expressions of estrogen receptor,progesterone receptor and human epidermal gro... Breast cancer is the most common type of female malignancy in the world.Triple-negative breast cancer refers to breast cancer in which the expressions of estrogen receptor,progesterone receptor and human epidermal growth factor receptor 2 are all negative.It has the clinical characteristics of easy invasion,high recurrence rate and short survival time.At present,there is a lack of effective treatment in the clinic.Following surgical treatment,chemotherapy,endocrine therapy,and molecular targeted therapy,a new type of treatment,immunotherapy,is of great significance for the treatment of triple-negative breast cancer. 展开更多
关键词 TRIPLE-NEGATIVE BREAST cancer IMMUNOTHERAPY Active IMMUNOTHERAPY PASSIVE IMMUNOTHERAPY TUMOR VACCINE
在线阅读 下载PDF
Advances in biological immunotherapy for gastric cancer:a mini-review 认领
3
作者 Wan-Qiu Lu 《TMR肿瘤》 2020年第2期74-83,共10页
Gastric cancer immunotherapy refers to the use of biological technology to mobilize the immune function so that the body has a natural anti-cancer ability.It can be induced in vitro by collecting immune cells and canc... Gastric cancer immunotherapy refers to the use of biological technology to mobilize the immune function so that the body has a natural anti-cancer ability.It can be induced in vitro by collecting immune cells and cancer cells from patients with gastric cancer to form specific immune cell groups.Besides,a large number of these immune cell groups are cultured,separated,and then reinfused into patients,to achieve high efficiency,eliminate tumors and mobilize immune mechanisms in patients.In theory,this method can cure tumors because the principle of immunotherapy is to stimulate the body's autoimmune response.However,for some special populations,there may be more severe side effects.At present,the prediction,prevention,and treatment of this severe side effect are not complete.The immunotherapy of gastric cancer has not yet reached the full promotion,but it is a good treatment direction.It can be used clinically with chemotherapy and radiotherapy,surgery and traditional Chinese medicine cooperate,thereby achieving significant curative effects,and even curing gastric cancer. 展开更多
关键词 Gastric cancer BIOLOGICAL IMMUNOTHERAPY Cell IMMUNOTHERAPY Tumor VACCINE therapy ADOPTIVE IMMUNOTHERAPY
在线阅读 下载PDF
嵌合抗原受体T细胞免疫疗法治疗血液系统恶性肿瘤的现状及其面临问题 认领
4
作者 徐玉林 胡永仙 +2 位作者 曾祥钧 于晓虹 黄河 《国际输血及血液学杂志》 CAS 2020年第1期1-7,共7页
急性淋巴细胞白血病(ALL)患者,经嵌合抗原受体T细胞(CAR-T)免疫疗法治疗后,可获得完全缓解(CR)。然而,目前多个因素制约CAR-T免疫疗法在血液系统恶性肿瘤和其他癌症,特别是实体瘤患者中的广泛应用。CAR-T免疫疗法临床应用的主要挑战包括... 急性淋巴细胞白血病(ALL)患者,经嵌合抗原受体T细胞(CAR-T)免疫疗法治疗后,可获得完全缓解(CR)。然而,目前多个因素制约CAR-T免疫疗法在血液系统恶性肿瘤和其他癌症,特别是实体瘤患者中的广泛应用。CAR-T免疫疗法临床应用的主要挑战包括:肿瘤抗原免疫逃逸导致的复发、细胞因子释放综合征(CRS)、CAR-T体内存活时间不理想、实体瘤内低浸润率和失活等。笔者拟就CAR-T免疫疗法在血液系统恶性肿瘤临床试验中的疗效和面临问题,以及如何利用综合性治疗方案和生物工程技术,解决目前存在问题的最新研究进展进行阐述,旨在提高CAR-T免疫疗法的安全性和有效性,扩大其在不同肿瘤患者中的临床效益。 展开更多
关键词 免疫疗法 过继 受体 嵌合抗原 血液肿瘤 嵌合抗原受体T细胞 实体肿瘤 嵌合抗原受体T细胞免疫疗法 综合疗法
Tuberculosis Infection in a Patient with Lung Cancer under PD-L1 Inhibition: A Case Report 认领
5
作者 Eleni Papadaki Manika Katerina +2 位作者 Boutis Anastasios Kioumis Ioannis Kontakiotis Theodoros 《结核病研究(英文)》 2020年第3期158-164,共7页
<b>Background: </b>Immune checkpoint inhibitors have made a great novelty in the treatment of various cancer types, showing favourable outcomes and good tolerance by cancer patients. Immune checkpoint inhi... <b>Background: </b>Immune checkpoint inhibitors have made a great novelty in the treatment of various cancer types, showing favourable outcomes and good tolerance by cancer patients. Immune checkpoint inhibitors enhance and promote anti-tumor immunity, which can result in a wide range of adverse events, termed as immune-related adverse events, which are characterized by excessive immunity response. Although immune related adverse events are not co<span>nsidered to be originated from infectious causes, cases of cancer patients developing active tuberculosis during treatment with immune checkpoint inhibitors have been reported. <b>Aim:</b> The aim of the current case report is to highlight the importance of including opportunistic infections, such as tuberculosis, in the differential diagnosis of complications in the treatment of cancer patients receiving immunotherap<span><span>y. <b>Case presentation</b>: This case report describes a 62-year-old Caucasian male patient who developed active pulmonary tuberculosis after treatment with Durvalumab, an anti-programmed death cell ligand-1 antibody, administered as therapy for non small cell lung cancer. The diagnosis was challenging because of the fact that the clinical presentation and the radiographic imaging were compatible with disease progression. <b>Conclusion:</b> Screening for active or latent tuberculosis should be part of everyday practice before the initial administration of immunotherapy in oncologic patients. 展开更多
关键词 TUBERCULOSIS Immune Checkpoint Inhibitors Durvalumab IMMUNOTHERAPY PD-L1
在线阅读 免费下载
Melatonin: A Powerful Integrative Adjunctive Agent for Oncology 认领
6
作者 Dino Prato 《癌症治疗(英文)》 2020年第9期571-596,共26页
Melatonin is an established hormone supplement and has been well recognized for its effect on the circadian cycle to improve sleep, REM (rapid eye movement), and aiding in jetlag recovery. The utility of melatonin ext... Melatonin is an established hormone supplement and has been well recognized for its effect on the circadian cycle to improve sleep, REM (rapid eye movement), and aiding in jetlag recovery. The utility of melatonin extends beyond sleep aid, however. This hormone also possesses less well-known antioxidant action and even robust anticancer activity. Melatonin may be a key supplement for addressing age-related neurologic decline while serving as a valuable adjunctive cancer treatment that reduces drug resistance in tumors and downregulates angiogenesis. In immunotherapy, melatonin activates Natural Killer (NK) cells nested within tumoral tissue and does not have the side effect profile of other immunoreactive agents used for chemotherapy. Since melatonin is found in high concentrations in the brain and other hormone-linked tissues, the relevance of melatonin is increased for the treatment of estrogen-linked cancers. The immunomodulatory effect of melatonin may also help with chronic inflammation seen in patients with autoimmune disorders. All of these effects together represent a unique and versatile therapeutic agent for integrative medicine. No other commercially available drug possesses all of these therapeutic mechanisms while having a very minimal side </span><span style="font-family:Verdana;">effect profile and being considered overall to be safe to use. Currently, melatonin is underutilized in medicine, especially in the field of integrative oncology and represents a crucial supportive adjuvant to improve the lives of patients</span><span style="font-family:Verdana;">. 展开更多
关键词 MELATONIN ONCOLOGY Immunotherapy Chronic Inflammation Autoimmune Envita Antioxidant Anticancer ANTIANGIOGENESIS TELOMERASE Metastasis ANTI-PROLIFERATION Pro-Apoptosis Immune System Activation Cancer Adjuvant Chemotherapy Synergy
在线阅读 免费下载
胃癌免疫治疗机制及临床应用的研究进展 认领
7
作者 欧凯 杨林 《中国肿瘤》 CAS CSCD 北大核心 2020年第2期125-133,共9页
胃癌是发病率最高的癌症之一。现有的放化疗及手术治疗方法对于晚期胃癌患者的效果欠佳。免疫疗法方兴未艾,有望成为治疗晚期胃癌的有效方法。胃癌患者常处于免疫抑制状态,且分子类型多样。目前免疫疗法临床前和临床试验主要包括免疫检... 胃癌是发病率最高的癌症之一。现有的放化疗及手术治疗方法对于晚期胃癌患者的效果欠佳。免疫疗法方兴未艾,有望成为治疗晚期胃癌的有效方法。胃癌患者常处于免疫抑制状态,且分子类型多样。目前免疫疗法临床前和临床试验主要包括免疫检查点抑制剂、过继性细胞免疫疗法和癌症疫苗。提高已有免疫疗法的安全性和有效性,根据胃癌患者的个体特征匹配合适的免疫疗法,寻找新的免疫疗法可能是未来免疫疗法的主要发展方向。 展开更多
关键词 胃肿瘤 免疫治疗 免疫检查点 过继免疫疗法 癌症疫苗
Correlation of Programmed Death Ligand-1 (PD-L1) Expression with Clinicopathological Features in Non-Small Cell Lung Carcinoma: Experience from a Tertiary Cancer Care Center in India 认领
8
作者 Hafsa Saif K. S. Rajesh Kumar +6 位作者 Suhail Sayeed Mufti Ritesh Giri V. Hrishi Vinu Sarathy Veena Ramaswamy Diganta Hazarika Radheshyam Naik 《癌症治疗(英文)》 2020年第3期172-187,共16页
Background:?According to the GLOBOCAN 2018 report, the estimated incidence of lung cancer in India was 67,795 in both sexes. The treatment of advanced Non-small cell lung cancer (NSCLC) saw a major paradigm shift with... Background:?According to the GLOBOCAN 2018 report, the estimated incidence of lung cancer in India was 67,795 in both sexes. The treatment of advanced Non-small cell lung cancer (NSCLC) saw a major paradigm shift with recent advances in molecular-targeted therapy. Immune checkpoint blockade therapy is one such novel strategy with promising clinical benefits in advanced NSCLC. Programmed cell death receptor-1/Programmed cell death ligand-1 (PD-1/PD-L1) pathway is one such checkpoint and has thus become the current area of interest in the treatment of lung carcinoma. The PD-1/?PD-L1 pathway is under active investigation as it represents a promising therapeutic target in NSCLC. The expression of PD-L1 in tumor cells has been suggested as a predictive marker of the clinical response to PD-1/?PD-L1-targeted therapy. Methods: This study was carried out at the Department of Pathology, Health Care Global Specialty Hospital, Bangalore from May 2018 to May 2019. In this study, we analyzed pattern of PD-L1 expression by immunohistochemistry testing using our own Laboratory Developed Test (LDT) in NSCLC patients. Results:?Our study group comprised 50 patients of NSCLC. Among our study population, 40% of the patients exhibited PD-L1 immunopositivity (≥1%) with 28% of them having any expression (TPS 1% - 49%) and 12% of them having a high expression (TPS ≥ 50%) of PD-L1. Majority of them exhibited adenocarcinoma type of NSCLC under which the solid subtype showed a direct correlation with PD-L1 positivity (p-value: 0.004) with a poorly differentiated tumor histology being common in our population in relation to PD-L1 positivity (p-value: 0.043). PD-L1 expression did not correlate with age, gender, smoking status or clinical stage in our study. No association was found between tumor histology (SCC or AC) and driver mutation status with expression of PD-L1 in the present study. Conclusions: In our study, PD-L1 immunopositivity was found in 40% of patients and majority of them exhibited adenocarcinoma type of NSCLC. There was 展开更多
关键词 Lung Cancer PD-L1 IHC BIOMARKER IMMUNOTHERAPY
在线阅读 免费下载
Combating 2019-nCoV Amidst the Pandemic Scare 认领
9
作者 Khawaja Husnain Haider Qurratulain Hyder 《再生医学期刊(英文)》 2020年第2期15-19,共5页
2019-nCoV is the third consecutive coronavirus spread during the last 2 decades, but this time, unlike the previous two occasions, has achieved a pandemic proportion threatening widespread loss of human lives and a ma... 2019-nCoV is the third consecutive coronavirus spread during the last 2 decades, but this time, unlike the previous two occasions, has achieved a pandemic proportion threatening widespread loss of human lives and a massive setback to the global economy. The situation warrants drastic measures in terms of preventing the spread of the virus and treating the virus-infected patients. The development of a new vaccine is a time-intensive option. Although efforts are underway to find possible pharmacological options, e.g., chloroquine, hydroxychloroquine, existing antiviral agents, etc., in the meanwhile we may work on the combinatorial interventional approach of combining drug therapy with passive immune therapy. It would be prudent to use a convalescent serum therapy approach with the serum from COVID-19 patients who have recovered from the infection. 展开更多
关键词 CORONAVIRUS COVID-19 IMMUNOTHERAPY PASSIVE CHLOROQUINE
在线阅读 免费下载
Type 1 diabetes mellitus and its oral tolerance therapy 认领
10
作者 Rui-Feng Mao Ying-Ying Chen +2 位作者 Ji Zhang Xin Chang Ye-Fu Wang 《世界糖尿病杂志:英文版(电子版)》 SCIE CAS 2020年第10期400-415,共16页
As a T cell-mediated autoimmune disease,type 1 diabetes mellitus(T1DM)is marked by insulin defect resulting from the destruction of pancreaticβ-cells.The understanding of various aspects of T1DM,such as its epidemiol... As a T cell-mediated autoimmune disease,type 1 diabetes mellitus(T1DM)is marked by insulin defect resulting from the destruction of pancreaticβ-cells.The understanding of various aspects of T1DM,such as its epidemiology,pathobiology,pathogenesis,clinical manifestations,and complications,has been greatly promoted by valuable research performed during the past decades.However,these findings have not been translated into an effective treatment.The ideal treatment should safely repair the destroyed immune balance in a longlasting manner,preventing or stopping the destruction ofβ-cells.As a type of immune hypo-responsiveness to the orally administrated antigen,oral tolerance may be induced by enhancement of regulatory T cells(Tregs)or by anergy/deletion of T cells,depending on the dosage of orally administrated antigen.Acting as an antigen-specific immunotherapy,oral tolerance therapy for T1DM has been mainly performed using animal models and some clinical trials have been completed or are still ongoing.Based on the review of the proposed mechanism of the development of T1DM and oral tolerance,we give a current overview of oral tolerance therapy for T1DM conducted in both animal models and clinical trials. 展开更多
关键词 Type 1 diabetes mellitus IMMUNOTHERAPY Oral tolerance Regulatory T cells Antigen-specific immunotherapy
在线阅读 免费下载
晚期胃癌免疫治疗的研究进展 认领
11
作者 戴佳丽 陈玥彤 +3 位作者 崔笑雯 顾冬英 俞华林 陈锦飞 《医学综述》 2020年第9期1718-1724,共7页
随着对肿瘤生物学行为及分子机制研究的深入,免疫治疗逐渐成为一种新型治疗策略,并取得了突飞猛进的发展。胃癌是我国常见的恶性肿瘤之一,发病率及死亡率均较高,但传统治疗方法的临床疗效有限。近年来,免疫治疗逐渐成为继手术、化疗、... 随着对肿瘤生物学行为及分子机制研究的深入,免疫治疗逐渐成为一种新型治疗策略,并取得了突飞猛进的发展。胃癌是我国常见的恶性肿瘤之一,发病率及死亡率均较高,但传统治疗方法的临床疗效有限。近年来,免疫治疗逐渐成为继手术、化疗、放疗及靶向治疗之后有效且有前景的治疗方法。免疫治疗主要利用自身的天然防御机制,杀伤肿瘤细胞,具有显著的抗肿瘤作用。免疫治疗的问世,给晚期胃癌的治疗提供了新思路,进一步提高了晚期胃癌患者的疗效。 展开更多
关键词 晚期胃癌 免疫治疗 免疫检查点抑制剂 过继性细胞免疫 免疫疫苗
在线阅读 下载PDF
ROS1 in Squamous Non-Small Cell Lung Cancer—Combined Immunotherapy (PD1/CTLA4) or Targeted Therapy? 认领
12
作者 Alexander Yakobson Tal Mor +7 位作者 Levitas Dina Laila C. Roisman Daniel Levin Wafeek Alguayn Sara Morgenstern Keren Rouvinov Nir Peled Waleed Kian 《癌症治疗(英文)》 2020年第6期365-370,共6页
ROS1 oncogenic fusion is reported to be 1%</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"... ROS1 oncogenic fusion is reported to be 1%</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> - </span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;">2% of non-small cell lung cancers (NSCLCs) of the adenocarcinoma subgroup. Meanwhile, there are no records of squamous cell cancer patients with tumors harboring ROS1 fusions. The Foundation Medicine database indicates a frequency of ROS1 rearrangements is 0.2% among squamous NSCLC. Crizotinib is known to be very effective in these patients</span><b><span style="font-family:Verdana;">.</span></b></span></span></span><span><span><b><span style="font-family:""> </span></b></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">Here we present a non-smoker patient who had pure squamous NSCLC that was treated by combinational immunotherapy under a clinical trial and progressed after 2 cycles. Surprisingly, comprehensive genomic profiling detected a rare oncogenic EZR-ROS1 fusion, and the patient was treated by crizotinib with a significant response within 6 weeks. To date, the patient has been on therapy for 42 months</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">and has achieved</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">a complete metabolic response. 展开更多
关键词 ROS1 CRIZOTINIB Squamous Cell Lung Cancer IMMUNOTHERAPY Non-Small Cell Lung Cancer
在线阅读 免费下载
非小细胞肺癌免疫治疗的相关研究进展 认领
13
作者 林海彬 何湛 《世界最新医学信息文摘》 2020年第53期88-90,共3页
肺癌是对人类健康威胁最大的恶性肿瘤之一,非小细胞肺癌是肺癌中最常见的组织类型,大多数患者在确诊时已处于晚期阶段。近年来,免疫治疗为非小细胞肺癌患者带来了新的曙光,有望成为新的治疗方向。在这篇综述中,我们旨在对非小细胞肺癌... 肺癌是对人类健康威胁最大的恶性肿瘤之一,非小细胞肺癌是肺癌中最常见的组织类型,大多数患者在确诊时已处于晚期阶段。近年来,免疫治疗为非小细胞肺癌患者带来了新的曙光,有望成为新的治疗方向。在这篇综述中,我们旨在对非小细胞肺癌免疫治疗的相关机制,最新研究方案进行论述,进一步分析了非小细胞肺癌免疫治疗的研究现状及面临的挑战,试图为未来的抗癌治疗提供见解和展望。 展开更多
关键词 非小细胞肺癌 免疫治疗 检查点抑制剂 标志物
在线阅读 下载PDF
Immune checkpoint inhibitors induced colitis, stay vigilant: A case report 认领
14
作者 Suha Abu Khalaf Abdulmajeed Albarrak +1 位作者 Mohamad Yousef Veysel Tahan 《世界胃肠肿瘤学杂志:英文版(电子版)》 SCIE CAS 2020年第6期699-704,共6页
BACKGROUND Colitis is one of the immune-related side effects of immunotherapy.Usually,such type of side effect was reported to develop within a few weeks of treatment initiation,our case started within a few days.CASE... BACKGROUND Colitis is one of the immune-related side effects of immunotherapy.Usually,such type of side effect was reported to develop within a few weeks of treatment initiation,our case started within a few days.CASE SUMMARY We present a case of a 37-year-old gentleman with bright red loose stools,abdominal pain,and tenesmus.A diagnosis of colitis was made based on endoscopic and histologic findings.Treatment was thereafter continued with oral steroids and discontinuation of the immunotherapy medications.Symptoms resolved after starting the treatment and the patient continued to be symptomfree on subsequent follow-up.The unique about this case report is that the patient developed bloody diarrhea within five days of the 1st immunotherapy cycle,and the patient was on combined ipilimumab and nivolumab.CONCLUSION Immunotherapy related complications might occur within days from being on immunotherapy;we need more research to open the way for future pathological and clinical research to further understand the pathophysiology behind it. 展开更多
关键词 Immunotherapy COLITIS MELANOMA Case report IPILIMUMAB Hepatitis
在线阅读 免费下载
高龄肺腺鳞癌患者免疫治疗一例并文献复习 认领
15
作者 李敏 许伟 +2 位作者 陈艳 吴双双 吴剑卿 《中华老年医学杂志》 CAS CSCD 北大核心 2020年第6期689-692,共4页
目的:探讨老年肺腺鳞癌患者免疫治疗及优化免疫相关不良反应的全程管理。方法:回顾分析1例83岁肺腺鳞癌晚期患者住院期间接受免疫治疗的临床资料,对老年肺癌患者免疫治疗临床特点进行分析。结果:老年肺腺鳞癌免疫治疗与年轻患者相比,有... 目的:探讨老年肺腺鳞癌患者免疫治疗及优化免疫相关不良反应的全程管理。方法:回顾分析1例83岁肺腺鳞癌晚期患者住院期间接受免疫治疗的临床资料,对老年肺癌患者免疫治疗临床特点进行分析。结果:老年肺腺鳞癌免疫治疗与年轻患者相比,有相似的临床获益及毒性反应,但老年人群存在免疫衰老及共患病,免疫相关并发症增加,如间质性肺炎进展等。结论:年龄在免疫治疗获益方面无显著性差别。对于合并多种并发症、衰弱症的高龄患者,老年综合评估可能有助于改善临床预后。 展开更多
关键词 肺肿瘤 免疫疗法 肺疾病 间质性
帕博利珠单抗引起免疫相关性结肠炎1例并文献复习 认领
16
作者 肖超 张清山 +2 位作者 牛文静 张海梅 宋海平 《青岛大学学报:医学版》 CAS 2020年第6期747-749,共3页
免疫治疗是目前肿瘤领域研究热点。免疫治疗在获得显著疗效的同时可能引起一系列免疫相关不良反应,可累及病人全身各个系统。我院收治1例宫颈癌病人行帕博利珠单抗治疗后出现免疫相关性结肠炎,表现为腹痛、腹泻、黏液血便,抗生素治疗无... 免疫治疗是目前肿瘤领域研究热点。免疫治疗在获得显著疗效的同时可能引起一系列免疫相关不良反应,可累及病人全身各个系统。我院收治1例宫颈癌病人行帕博利珠单抗治疗后出现免疫相关性结肠炎,表现为腹痛、腹泻、黏液血便,抗生素治疗无效,给予大剂量糖皮质激素治疗后好转。本文对该病例临床资料进行分析,并复习相关文献,探讨免疫相关性结肠炎的发病机制、临床特点、鉴别诊断及治疗原则。 展开更多
关键词 免疫疗法 宫颈肿瘤 帕博利珠单抗 结肠炎 药物相关性副作用和不良反应
在线阅读 下载PDF
外泌体在胶质瘤中的研究进展 认领
17
作者 蒋航 陈波 +1 位作者 曾雪 张云东 《中国肿瘤》 CAS CSCD 北大核心 2020年第10期777-786,共10页
胶质瘤是常见的原发性脑肿瘤,具有高侵袭性、高复发性、高致死率的特点。外泌体是由细胞分泌的功能性囊泡结构,普遍存在于生物体液中,其具有广泛的内容物,并参与了多种生理和病理过程,尤其是肿瘤的发生发展。外泌体可诱导受体细胞产生... 胶质瘤是常见的原发性脑肿瘤,具有高侵袭性、高复发性、高致死率的特点。外泌体是由细胞分泌的功能性囊泡结构,普遍存在于生物体液中,其具有广泛的内容物,并参与了多种生理和病理过程,尤其是肿瘤的发生发展。外泌体可诱导受体细胞产生大量的生物学过程,与肿瘤的形成、发展、转移、浸润和耐药性等密切相关。外泌体在胶质瘤的诊断及治疗中的作用也日益受到重视,胶质瘤外泌体的特异性成分可作为诊断和预测生物标志物,外泌体也可作为运送抗癌药物的载体,经修饰的外泌体可以用于胶质瘤的免疫治疗。本文综述了外泌体在胶质瘤进展中的重要作用及其对诊断和新治疗策略发展的意义。 展开更多
关键词 胶质瘤 外泌体 肿瘤微环境 生物标志物 免疫治疗
双表达弥漫大B细胞淋巴瘤自体造血干细胞移植复发后嵌合抗原受体T细胞免疫治疗持续缓解一例并文献复习 认领
18
作者 林玉奇 陈香丽 +4 位作者 臧玉柱 张磊 张文荟 孙恺 王亚彩 《白血病.淋巴瘤》 CAS 2020年第5期288-290,共3页
目的探讨双表达淋巴瘤患者自体造血干细胞移植复发后嵌合抗原受体T细胞(CAR-T)的治疗效果。方法回顾性分析1例于2017年8月就诊于河南省人民医院且在自体造血干细胞移植复发后接受CAR-T治疗的双表达弥漫大B细胞淋巴瘤患者的治疗过程,并... 目的探讨双表达淋巴瘤患者自体造血干细胞移植复发后嵌合抗原受体T细胞(CAR-T)的治疗效果。方法回顾性分析1例于2017年8月就诊于河南省人民医院且在自体造血干细胞移植复发后接受CAR-T治疗的双表达弥漫大B细胞淋巴瘤患者的治疗过程,并复习相关文献。结果该例50岁女性双表达弥漫大B细胞淋巴瘤患者,经标准方案化疗后以BEAM为预处理方案行自体造血干细胞移植,移植后5个月复发,后经含克拉屈滨的化疗方案治疗2个疗程,桥接CAR-T治疗,获得持续缓解,且持续8个月患者体内能检测到CD20+-CAR-T。结论对于自体造血干细胞移植后复发的非霍奇金淋巴瘤患者,先采用含克拉屈滨的方案诱导缓解后行序贯CAR-T治疗可能是一个较好的选择。 展开更多
关键词 淋巴瘤 大B-细胞 弥漫性 造血干细胞移植 克拉屈滨 嵌合抗原受体T细胞 免疫疗法
嵌合抗原受体T细胞治疗淋巴瘤的现状及展望 认领
19
作者 朱祎静 张仪 +1 位作者 尤良顺 童向民 《中国肿瘤》 CAS CSCD 北大核心 2020年第10期787-791,共5页
近年来,随着免疫治疗和基因工程的兴起,嵌合型抗原受体T细胞疗法(chimeric antigen receptor T-cell immunotherapy,CART)由于其安全有效、患者耐受性好的特点,为复发/难治的淋巴瘤患者带来了新的希望。本文综述了CART的原理及免疫机制... 近年来,随着免疫治疗和基因工程的兴起,嵌合型抗原受体T细胞疗法(chimeric antigen receptor T-cell immunotherapy,CART)由于其安全有效、患者耐受性好的特点,为复发/难治的淋巴瘤患者带来了新的希望。本文综述了CART的原理及免疫机制、CART在淋巴瘤中的应用、CART治疗面临的问题及CART治疗淋巴瘤的未来及展望。 展开更多
关键词 CART治疗 B细胞淋巴瘤 霍奇金淋巴瘤 免疫治疗
他克莫司与环孢素主导肝移植术后免疫治疗致肾损伤的队列研究 认领
20
作者 赵敏 李亚娟 +5 位作者 景桂霞 高媛 张文瑞 王鸽 沙保勇 高巍 《实用药物与临床》 CAS 2020年第2期122-129,共8页
目的比较他克莫司和环孢素在肝移植术后急性排斥反应期内(术后8 d)肾功能损伤程度的差异。方法回顾性纳入西安交通大学第一附属医院2016年6月至2017年6月肝移植患者,年龄18~75岁,术后均接受8 d以上三联免疫抑制治疗,即在吗替麦考酚酯、... 目的比较他克莫司和环孢素在肝移植术后急性排斥反应期内(术后8 d)肾功能损伤程度的差异。方法回顾性纳入西安交通大学第一附属医院2016年6月至2017年6月肝移植患者,年龄18~75岁,术后均接受8 d以上三联免疫抑制治疗,即在吗替麦考酚酯、糖皮质激素基础上,联合他克莫司或环孢素,并将患者分为他克莫司组或环孢素组。排除多次肝移植、住院期间因手术并发症原因死亡患者。比较患者的基本信息后,用R语言统计系统进行肾功能相关指标单因素及多因素回归分析。结果本研究共纳入93例患者,排除1年内进行2次肝移植患者1例,住院期间因手术并发症原因死亡患者1例,最终入组91例患者。术前和用药前肾功能指标相比较,尿素氮和肌酐的升高、肾小球滤过率的降低差异有统计学意义(P<0.05),表明手术可以导致肾损伤。用药前肾功能的各项指标差异无统计学意义,均具有可比性。采用单因素筛选及多因素回归分析与环孢素组比较:他克莫司组肾小球滤过率增加19.63 ml/(min·1.73 m^2)(95%CI:7.20~32.06,P<0.01);调整混杂因素乙肝、丙肝、自身免疫性肝炎、性别后,他克莫司组肌酐降低8.58μmol/L(95%CI:-14.87~-2.30,P<0.01);他克莫司组尿素氮降低1.57 mmol/L(95%CI:-2.92~-0.22,P<0.05);他克莫司组尿酸降低44.55μmol/L(95%CI:-73.76~-15.34,P<0.01)。结论肝移植手术本身可以导致肾损伤,在术后免疫治疗急性排斥反应期内,他克莫司对肾功能的损伤程度显著低于环孢素。 展开更多
关键词 肝移植 免疫治疗 肾功能损伤 他克莫司 环孢素
在线阅读 下载PDF
上一页 1 2 250 下一页 到第
使用帮助 返回顶部 意见反馈